Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.

Abstract:

:Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant congenital disorder characterized by progressive heterotopic bone formation. Currently, no definitive treatment exists for FOP. The activin receptor type IA / activin-like kinase 2 (ACVR1/ALK2) gene has been identified as the responsible gene for FOP, and disease-associated ALK2 mutations have been found. Chemical inhibitors to the pathogenic ALK2 receptors are considered possible medical agents for FOP, but their adverse effects on normal ALK2 and other receptors cannot be excluded. Here we describe another treatment strategy for FOP using allele-specific RNA interference (ASP-RNAi), and show modified small interfering RNAs (siRNAs) conferring allele-specific silencing against disease-causing ALK2 mutants found in FOP, without affecting normal ALK2 allele. Thus, the siRNAs presented here may become novel therapeutic agents for FOP, and their induced ASP-RNAi may pave the way for the achievement of radical treatment of FOP and/or for the relief of its severe symptoms.

journal_name

Gene Ther

journal_title

Gene therapy

authors

Takahashi M,Katagiri T,Furuya H,Hohjoh H

doi

10.1038/gt.2011.193

subject

Has Abstract

pub_date

2012-07-01 00:00:00

pages

781-5

issue

7

eissn

0969-7128

issn

1476-5462

pii

gt2011193

journal_volume

19

pub_type

杂志文章
  • Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA.

    abstract::Inhibition of virus replication by means of RNA interference has been reported for several important human pathogens, including human immunodeficiency virus type 1 (HIV-1). RNA interference against these pathogens has been accomplished by introduction of virus-specific synthetic small interfering RNAs (siRNAs) or DNA ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302786

    authors: Konstantinova P,de Vries W,Haasnoot J,ter Brake O,de Haan P,Berkhout B

    更新日期:2006-10-01 00:00:00

  • RNAi-mediated gene silencing in tumour tissue using replication-competent retroviral vectors.

    abstract::RNAi represents a powerful technology to specifically downregulate the expression of target genes. For cancer research and therapy, an efficient in vivo delivery system is supposed to distribute RNAi to all tumour cells upon systemic administration. We present replication-competent murine leukaemia virus (MLV) vectors...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2011.48

    authors: Schaser T,Wrede C,Duerner L,Sliva K,Cichutek K,Schnierle B,Buchholz CJ

    更新日期:2011-10-01 00:00:00

  • Angiogenic and antiangiogenic gene therapy.

    abstract::Gene therapy is thought to be a promising method for the treatment of various diseases. One gene therapy strategy involves the manipulations on a process of formation of new vessels, commonly defined as angiogenesis. Angiogenic and antiangiogenic gene therapy is a new therapeutic approach to the treatment of cardiovas...

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/sj.gt.3302621

    authors: Malecki M,Kolsut P,Proczka R

    更新日期:2005-10-01 00:00:00

  • Percutaneous gene therapy heals cranial defects.

    abstract::Nonhealing bone defects are difficult to treat. As the bone morphogenic protein and transforming growth factor beta pathways have been implicated in bone healing, we hypothesized that percutaneous Smad7 silencing would enhance signaling through both pathways and improve bone formation. Critical sized parietal trephine...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2013.15

    authors: Layliev J,Sagebin F,Weinstein A,Marchac A,Szpalski C,Saadeh PB,Warren SM

    更新日期:2013-09-01 00:00:00

  • A novel magnetic approach to enhance the efficacy of cell-based gene therapies.

    abstract::Attempts have been made to use various forms of cellular vectors to deliver therapeutic genes to diseased tissues like malignant tumours. However, this approach has proved problematic due to the poor uptake of these vectors by the target tissue. We have devised a novel way of using magnetic nanoparticles (MNPs) to enh...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2008.57

    authors: Muthana M,Scott SD,Farrow N,Morrow F,Murdoch C,Grubb S,Brown N,Dobson J,Lewis CE

    更新日期:2008-06-01 00:00:00

  • Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.

    abstract::Gene therapy with Plasmid AMEP (antiangiogenic metargidin peptide) has recently been studied as a potential targeted therapy for melanoma. This plasmid is designed to downregulate α5β1 and αvβ3 integrins. In our study, electroporation was used as a nonviral delivery system. We investigated the antiangiogenic and direc...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2015.26

    authors: Bosnjak M,Dolinsek T,Cemazar M,Kranjc S,Blagus T,Markelc B,Stimac M,Zavrsnik J,Kamensek U,Heller L,Bouquet C,Turk B,Sersa G

    更新日期:2015-07-01 00:00:00

  • Effective treatment of vascular endothelial growth factor refractory hindlimb ischemia by a mutant endothelial nitric oxide synthase gene.

    abstract::Gene delivery of angiogenic growth factors is a promising approach for the treatment of ischemic cardiovascular diseases. However, success of this new therapeutic principle is hindered by the lack of critical understanding as to how disease pathology affects the efficiency of gene delivery and/or the downstream signal...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302781

    authors: Qian HS,Liu P,Huw LY,Orme A,Halks-Miller M,Hill SM,Jin F,Kretschmer P,Blasko E,Cashion L,Szymanski P,Vergona R,Harkins R,Yu J,Sessa WC,Dole WP,Rubanyi GM,Kauser K

    更新日期:2006-09-01 00:00:00

  • Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes.

    abstract::The E1 deleted adenoviral vectors are efficient at gene transfer to cells in culture or in animals. However, their use is limited because of an immune-mediated loss of transduced cells. This immune response is believed to result from low-level production of viral antigens from these vectors after gene transfer. The ea...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:

    authors: Scaria A,Curiel DT,Kay MA

    更新日期:1995-06-01 00:00:00

  • Enhanced transduction efficiency of retroviral vectors coprecipitated with calcium phosphate.

    abstract::Retroviral vectors are being used increasingly in clinical gene therapy protocols but low transduction frequencies are presenting a significant obstacle to progress. In this paper we report a simple method to enhance the efficiency of ex vivo retroviral gene transfer. Calcium chloride is added to the vector stock and ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:

    authors: Morling FJ,Russell SJ

    更新日期:1995-09-01 00:00:00

  • Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig.

    abstract::Adenoviral vectors deleted of E1 are attractive vehicles for in vivo gene therapy because efficient gene transfer can be achieved. Immune responses to the vector and vector-transduced cells lead to destruction of target cells, inflammation and difficulties with vector readministration. Immune effectors have been ident...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300595

    authors: Jooss K,Turka LA,Wilson JM

    更新日期:1998-03-01 00:00:00

  • Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines.

    abstract::Cellular immunity against cancer can be achieved with viral vector- and DNA-based immunizations. In preclinical studies, cancer vaccines are very potent, but in clinical trials these potencies are not achieved yet. Thus, a rational approach to improve cancer vaccines is warranted. We previously demonstrated that the r...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2015.24

    authors: Ip PP,Boerma A,Walczak M,Oosterhuis K,Haanen JB,Schumacher TN,Nijman HW,Daemen T

    更新日期:2015-07-01 00:00:00

  • Encapsulated engineered myoblasts can cure Hurler syndrome: preclinical experiments in the mouse model.

    abstract::Mucopolysaccharidosis type I (MPSI) is an autosomic recessive, lysosomal storage disorder due to the deficit of the enzyme α-L-iduronidase (IDUA). The disease accounts for a general impairment of tissue and organ functions, mainly including heart disease, corneal clouding, organomegaly, skeletal malformations and join...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2011.94

    authors: Piller Puicher E,Tomanin R,Salvalaio M,Friso A,Hortelano G,Marin O,Scarpa M

    更新日期:2012-04-01 00:00:00

  • Intrabodies: turning the humoral immune system outside in for intracellular immunization.

    abstract::Antibodies have long been used in biomedical science as in vitro tools for the identification, purification and functional manipulation of target antigens; they have been exploited in vivo for diagnostic and therapeutic applications as well. Recent advances in antibody engineering have now allowed the genes encoding a...

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/sj.gt.3300346

    authors: Marasco WA

    更新日期:1997-01-01 00:00:00

  • Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes.

    abstract::Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates blood glucose level post-prandially. It has been proposed that GLP-1 can be used in type 2 diabetes (T2D) mellitus treatment because of its insulinotropic action. Despite its remarkable advantages, GLP-1 suffers the disadvantage of an extremely shor...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2011.25

    authors: Jean M,Alameh M,Buschmann MD,Merzouki A

    更新日期:2011-08-01 00:00:00

  • Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.

    abstract::Interferon-alpha (IFN-alpha) or CD80 transduction of tumor cells individually reduces tumorigenicity and enhances antitumor responses. Here, we report that the combination of IFN-alpha and CD80 cancer gene therapy in poorly immunogenic murine tumor models, the colorectal adenocarcinoma cell line MC38, and the methylch...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301034

    authors: Hiroishi K,Tüting T,Tahara H,Lotze MT

    更新日期:1999-12-01 00:00:00

  • Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis.

    abstract::To evaluate the use of HSV-based vectors for arthritis gene therapy we have constructed a first-generation, ICP4 deficient, replication defective herpes simplex virus (HSV) vector (S/0-) and a second-generation HSV vector derivative (T/0-) deficient for the immediate-early genes ICP4, 22 and 27, each carrying a solubl...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301014

    authors: Oligino T,Ghivizzani S,Wolfe D,Lechman E,Krisky D,Mi Z,Evans C,Robbins P,Glorioso J

    更新日期:1999-10-01 00:00:00

  • Functional and phenotypic variations in human T cells subjected to retroviral-mediated gene transfer.

    abstract::The insertion of suicide genes in donor T lymphocytes constitutes the basis of new approaches aiming at the treatment of the graft-versus-host disease (GVHD), a frequent complication in recipients of allogeneic haematopoietic grafts. In this study we investigated the impact that the ex vivo manipulation required for t...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302188

    authors: Lamana ML,Bueren JA,Vicario JL,Balas A

    更新日期:2004-03-01 00:00:00

  • Correction of argininosuccinate synthetase (AS) deficiency in a murine model of citrullinemia with recombinant adenovirus carrying human AS cDNA.

    abstract::Citrullinemia is an autosomal recessive disorder caused by the deficiency of argininosuccinate synthetase (AS). It is characterized by elevated levels of blood citrulline and ammonia, which often results in hyperammonemic coma and early neonatal death in affected children. We have explored the use of adenoviral vector...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301303

    authors: Ye X,Whiteman B,Jerebtsova M,Batshaw ML

    更新日期:2000-10-01 00:00:00

  • CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.

    abstract::Adoptive immunotherapy of cancer using chimeric antigen receptor (CAR)-engineered T cells with redirected specificity showed efficacy in recent trials. In preclinical models, 'second-generation' CARs with CD28 costimulatory domain in addition to CD3ζ performed superior in redirecting T-cell effector functions and surv...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2010.127

    authors: Chmielewski M,Hombach AA,Abken H

    更新日期:2011-01-01 00:00:00

  • Redirecting adenovirus to pulmonary endothelium by cationic liposomes.

    abstract::Somatic gene transfer to the pulmonary endothelium may be a useful strategy for modifying the phenotype of endothelium and/or vascular smooth muscle in disorders such as primary pulmonary hypertension, ARDS or pulmonary metastatic disease. Adenoviral (Ad) vectors, although highly efficient in liver gene transfer, have...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301636

    authors: Ma Z,Mi Z,Wilson A,Alber S,Robbins PD,Watkins S,Pitt B,Li S

    更新日期:2002-02-01 00:00:00

  • Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library.

    abstract::Selection of targeted vectors from virus display peptide libraries is a versatile and efficient approach to improve vector specificity and efficiency. This strategy has been used to target various cell types in vitro. Here, we report the screening of an adeno-associated virus type 2 (AAV2) display peptide library in v...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2010.44

    authors: Ying Y,Müller OJ,Goehringer C,Leuchs B,Trepel M,Katus HA,Kleinschmidt JA

    更新日期:2010-08-01 00:00:00

  • Foamy virus--adenovirus hybrid vectors.

    abstract::To confer adenovirus vectors (AdV), the feature of integration into the host cell genome hybrid vectors were characterized in vitro, which express vectors derived from the prototypic foamy virus (FV) in the backbone of a high-capacity AdV. FVs constitute a subfamily of retroviruses with a distinct replication pathway ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302216

    authors: Picard-Maureau M,Kreppel F,Lindemann D,Juretzek T,Herchenröder O,Rethwilm A,Kochanek S,Heinkelein M

    更新日期:2004-04-01 00:00:00

  • Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.

    abstract::Overexpression of vascular endothelial growth factor (VEGF) and its cognate receptor KDR has been linked to a more aggressive phenotype of human prostate carcinomas. The importance of signal transduction through the VEGF receptor 2 is illustrated by use of soluble KDR, which binds to VEGF and sequesters this ligand be...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302432

    authors: Kaliberov SA,Kaliberova LN,Buchsbaum DJ

    更新日期:2005-03-01 00:00:00

  • Mechanism by which calcium phosphate coprecipitation enhances adenovirus-mediated gene transfer.

    abstract::Delivery of a normal copy of CFTR cDNA to airway epithelia may provide a novel treatment for cystic fibrosis lung disease. Unfortunately, current vectors are inefficient because of limited binding to the apical surface of airway epithelia. We recently reported that incorporation of adenovirus in a calcium phosphate co...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301020

    authors: Walters R,Welsh M

    更新日期:1999-11-01 00:00:00

  • Bystander effect of purine nucleoside analogues in HSV-1 tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues.

    abstract::Introduction of the herpes simplex virus type 1 thymidine kinase gene into tumor cells, followed by the administration of the antiherpes nucleoside analogue ganciclovir has been demonstrated to be effective in eliminating solid tumors in animals. The success of this combination treatment largely depends on the bystand...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300806

    authors: Degrève B,De Clercq E,Balzarini J

    更新日期:1999-02-01 00:00:00

  • Virally expressed connexin26 restores gap junction function in the cochlea of conditional Gjb2 knockout mice.

    abstract::Mutations in GJB2, which codes for the gap junction (GJ) protein connexin26 (Cx26), are the most common causes of human nonsyndromic hereditary deafness. We inoculated modified adeno-associated viral (AAV) vectors into the scala media of early postnatal conditional Gjb2 knockout mice to drive exogenous Cx26 expression...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2013.59

    authors: Yu Q,Wang Y,Chang Q,Wang J,Gong S,Li H,Lin X

    更新日期:2014-01-01 00:00:00

  • Engineering physiologically regulated insulin secretion in non-beta cells by expressing glucagon-like peptide 1 receptor.

    abstract::Glucagon-like peptide 1 (GLP-1) is released from neuroendocrine cells in the intestine in the postprandial state and augments glucose-stimulated insulin secretion from pancreatic beta cells. To develop non-beta cells that exhibit physiologically regulated insulin secretion, we coexpressed the GLP-1 receptor and human ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302055

    authors: Wu L,Nicholson W,Wu CY,Xu M,McGaha A,Shiota M,Powers AC

    更新日期:2003-09-01 00:00:00

  • Identification of an alveolar type I epithelial cell-specific DNA nuclear import sequence for gene delivery.

    abstract::The ability to restrict gene delivery and expression to particular cell types is of paramount importance for many types of gene therapy, especially in the lung. The alveolar epithelial type I (ATI) cell, in particular, is an attractive cell type to target, as it comprises 95% of the internal surface area of the lung. ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2016.52

    authors: Gottfried L,Lin X,Barravecchia M,Dean DA

    更新日期:2016-10-01 00:00:00

  • Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals.

    abstract::Abnormal excitation-contraction coupling is a key pathophysiologic component of heart failure (HF), and at a molecular level reduced expression of the sarcoplasmic reticulum (SR) Ca(2+) ATPase (SERCA2a) is a major contributor. Previous studies in small animals have suggested that restoration of SERCA function is benef...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2008.120

    authors: Byrne MJ,Power JM,Preovolos A,Mariani JA,Hajjar RJ,Kaye DM

    更新日期:2008-12-01 00:00:00

  • Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.

    abstract::Intraperitoneal (i.p.) recurrence of cisplatin-refractory and p53 mutant ovarian cancer is a major clinical problem, despite surgery and chemotherapy. dl1520 (ONYX-015) is an E1B-55 kDa gene-deleted adenovirus engineered selectively to replicate in and destroy cancer cells lacking functional p53. However, a correlatio...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301319

    authors: Heise C,Ganly I,Kim YT,Sampson-Johannes A,Brown R,Kirn D

    更新日期:2000-11-01 00:00:00